Pielaciński Konrad, Puła Bartosz, Szczepanik Andrzej B
Department of General, Oncologic and Metabolic Surgery, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Wideochir Inne Tech Maloinwazyjne. 2021 Sep;16(3):552-559. doi: 10.5114/wiitm.2021.103953. Epub 2021 Feb 26.
Laparoscopic surgery is associated with several advantages. Surgical procedures in hemophilia or von Willebrand patients without replacement therapy (RT) to correct clotting factor deficiency may result in serious, life-threatening hemorrhagic episodes. Clotting factor concentrates improve hemostatic control but bleeding risk in major invasive procedures remains high.
Evaluation of totally extraperitoneal inguinal hernia repair (TEP-IHR) in patients with congenital hemorrhagic disorders (H) and comparison with results for non-hemophiliacs (NH) with regard to bleeding, postoperative pain, hernia recurrence, surgery time, demand for painkillers, hospital stay and recovery time.
The prospective controlled trial included 67 consecutive male patients scheduled for TEP-IHR between January 2010 and December 2018. Surgery was performed in groups H (n = 22) and NH (n = 45). Full study inclusion criteria were met by 65 patients (22 and 43 in H and NH groups respectively). Follow-up was carried out on the 1, 2, and 7 day and in the 1st and 3rd month postoperatively.
TEP-IHR was successful for all patients. No life-threatening bleeding occurred and no patient required red blood cell transfusions or reoperation. No hernia recurrence was reported. No statistically significant differences were observed between the groups with regard to surgery duration, postoperative hematoma frequency and demand for painkillers. In the H group, pain intensity was significantly higher during the first postoperative month and hospitalization and recovery were significantly longer.
TEP-IHR in hemophiliacs with RT is feasible and as effective for preventing hernia recurrence as in NH-patients. In hemophiliacs risk of bleeding complications and demand for painkillers are comparable to non-hemophiliacs although pain is more intense.
腹腔镜手术具有多种优势。在血友病或血管性血友病患者中,若不进行替代治疗(RT)以纠正凝血因子缺乏,手术操作可能会导致严重的、危及生命的出血事件。凝血因子浓缩剂可改善止血控制,但在大型侵入性手术中出血风险仍然很高。
评估先天性出血性疾病(H)患者的完全腹膜外腹股沟疝修补术(TEP-IHR),并在出血、术后疼痛、疝复发、手术时间、止痛药需求、住院时间和恢复时间方面与非血友病患者(NH)的结果进行比较。
这项前瞻性对照试验纳入了2010年1月至2018年12月期间计划进行TEP-IHR的67例连续男性患者。手术在H组(n = 22)和NH组(n = 45)中进行。65例患者(H组和NH组分别为22例和43例)符合全部研究纳入标准。术后第1、2、7天以及第1和3个月进行随访。
所有患者的TEP-IHR均成功。未发生危及生命的出血,也没有患者需要输注红细胞或再次手术。未报告疝复发。两组在手术持续时间、术后血肿发生率和止痛药需求方面未观察到统计学显著差异。在H组中,术后第一个月疼痛强度明显更高,住院时间和恢复时间明显更长。
接受RT的血友病患者进行TEP-IHR是可行的,在预防疝复发方面与NH患者一样有效。在血友病患者中,出血并发症风险和止痛药需求与非血友病患者相当,尽管疼痛更剧烈。